Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Endocrinology and metabolism indexChapter sections
Purpose and principlesIndications, selection and cautionsAssessment before treatmentTreatment approachRegimens, contraindications and interactionsComplications, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook10 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Dyslipidaemia and statin treatment

Endocrinology and metabolism · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

A lipid result alone rarely requires emergency treatment. Same-day assessment is needed for triglycerides with acute pancreatitis symptoms, rhabdomyolysis with weakness or dark urine, or an acute coronary, cerebrovascular or limb-ischaemia syndrome; do not delay vascular treatment to obtain a fasting lipid profile.

Purpose and principles

Interpret lipid patterns in cardiovascular context, identify secondary and familial disease, and use statins and add-on therapy to evidence-based UK targets with safe monitoring.

Dyslipidaemia is a pattern, not one number. Raised LDL drives atherosclerosis; high triglycerides can mark metabolic disease and, at severe concentrations, pancreatitis risk; low HDL often reflects insulin resistance but is not a direct drug target. Non-HDL cholesterol captures all atherogenic apoB-containing particles and remains usable in non-fasting samples.

Treatment intensity follows absolute cardiovascular risk and disease status. QRISK3 supports primary prevention in appropriate adults, but is not needed when vascular disease already exists and can underestimate lifetime or disease-specific risk in familial hypercholesterolaemia, significant chronic kidney disease and some diabetes contexts. Discuss absolute benefit, adverse effects, interactions and the option to revisit rather than framing the decision as compliance.

Statin-associated symptoms require structured dechallenge, differential assessment and rechallenge when safe. Exercise, hypothyroidism, vitamin D deficiency, inflammatory myopathy and drug interactions can mimic or amplify muscle complaints. A lower dose, different statin or nondaily specialist strategy often preserves benefit; true severe myopathy or rhabdomyolysis requires immediate cessation and acute care.

Key points

Indications, selection and cautions

LDL-predominant pattern

Raised LDL and non-HDL with relatively normal triglycerides suggests primary hypercholesterolaemia, diet, hypothyroidism, nephrotic disease or familial hypercholesterolaemia depending on magnitude and history.

Atherogenic metabolic pattern

Raised triglycerides, low HDL and small dense LDL tendency often accompanies central adiposity, type 2 diabetes, steatotic liver and alcohol excess; address each risk factor rather than targeting HDL pharmacologically.

Familial clue

Very high untreated cholesterol, tendon xanthomata or premature coronary disease in the patient or close relatives should trigger an FH pathway, not ordinary QRISK-based reassurance.

Statin myalgia

Symmetrical proximal aching or weakness temporally related to treatment may be statin-associated, but examination, CK when symptomatic, thyroid status, exercise and interacting medicines refine causality.

RhabdomyolysisRed flag

Severe muscle pain or weakness, dark urine, marked CK rise, hyperkalaemia or acute kidney injury demands immediate statin cessation, hospital assessment and interaction review.

Severe triglyceride stateRed flag

Triglycerides above 10 mmol/L, particularly above 20 or with abdominal pain, require urgent fasting confirmation, secondary-cause treatment and specialist planning for pancreatitis prevention.

Assessment before treatment

  1. 01
    Non-fasting full lipid profileFirst step
    Why
    Characterise atherogenic cholesterol and screen triglyceride severity conveniently.
    Interpretation and limitations
    Use total, HDL, non-HDL and triglycerides; calculated LDL becomes unreliable at high triglycerides, so follow non-HDL or specialist direct testing.
  2. 02
    QRISK3 assessment
    Why
    Estimate ten-year cardiovascular risk for appropriate primary-prevention adults.
    Interpretation and limitations
    Offer atorvastatin 20 mg at 10% or more after discussion; consider treatment below threshold when risk is underestimated or the informed person prefers it.
  3. 03
    Baseline ALT or AST and renal function
    Why
    Establish prescribing safety and identify liver or kidney comorbidity.
    Interpretation and limitations
    Transaminases below three times the upper limit do not routinely prohibit statin use; severe unexplained abnormality needs cause assessment and product-specific dosing review.
  4. 04
    HbA1c, TSH and secondary-cause screen
    Why
    Identify diabetes, hypothyroidism and other reversible lipid drivers.
    Interpretation and limitations
    Choose tests from history and examination, including urine protein when nephrotic disease is possible and alcohol or medicine review for triglyceride elevation.

Treatment approach

01Primary preventionTreat absolute vascular riskFirst stepAn adult without established cardiovascular disease is being considered for lipid lowering.+
  1. 1Obtain a lipid profile, blood pressure, smoking, diabetes, renal and family history, exclude major secondary causes and calculate QRISK3 when the tool is appropriate.
  2. 2Optimise lifestyle and offer atorvastatin 20 mg when ten-year risk is at least 10%, also discussing treatment below threshold when risk may be underestimated.
  3. 3Repeat lipids and liver tests in two to three months, aiming for more than 40% non-HDL reduction and addressing adherence or intensity if response is insufficient.
02Secondary preventionStart high intensity without delayCoronary, cerebrovascular or peripheral arterial disease is established.+
  1. 1Offer atorvastatin 80 mg as soon as clinically appropriate without using QRISK, choosing a lower dose only for interaction, adverse-effect risk or informed preference.

Regimens, contraindications and interactions

Reduces LDL-related atherosclerotic events in people whose absolute or lifetime risk justifies pharmacological prevention.

Atorvastatin for primary prevention

Take 20 mg orally once daily when NICE primary-prevention criteria and shared decision-making support treatment; increase intensity if the non-HDL response remains below target after adherence review.

Avoid in pregnancy and breastfeeding; review liver disease, grapefruit intake and strong CYP3A4 interactions. Investigate significant muscle symptoms and use a lower or different statin when tolerability limits benefit.

High-intensity secondary prevention after coronary, cerebrovascular or peripheral arterial disease.

Atorvastatin for secondary prevention

Take 80 mg orally once daily for established cardiovascular disease unless interactions, adverse-effect risk or patient preference support a lower dose, then maximise the tolerated intensity.

Do not delay acute vascular care for baseline lipids. Check current BNF interactions, hepatic status and reproductive plans; severe weakness, dark urine or marked CK elevation requires immediate cessation and assessment.

Reduces intestinal cholesterol absorption and provides additional LDL and non-HDL lowering.

Ezetimibe

Take 10 mg orally once daily, usually added to maximally tolerated statin or used when statin therapy is contraindicated or genuinely not tolerated under NICE guidance.

Review liver tests when combined with statin, pregnancy and breastfeeding, ciclosporin and biliary disease. Confirm adherence and the indication before escalating to injectable therapy.

Complications, monitoring and follow-up

  • Repeat full lipid profile and liver transaminases two to three months after starting or changing lipid-lowering treatment and document percentage non-HDL change.
  • For primary prevention, seek more than 40% non-HDL reduction; for secondary prevention, seek LDL at most 2.0 or non-HDL at most 2.6 mmol/L.
  • Measure liver transaminases again at twelve months and thereafter only when clinically indicated, rather than stopping effective therapy for routine minor fluctuation.
  • Ask about adherence, affordability, formulation, interactions and muscle symptoms before declaring pharmacological failure or escalating treatment.
  • Check CK only when muscle symptoms occur, and monitor renal function, potassium and urine in suspected rhabdomyolysis through acute care.
  • Review diabetes risk and HbA1c according to the person's baseline status without withholding statin when cardiovascular benefit outweighs the modest glycaemic effect.
  • Revisit pregnancy plans and breastfeeding at relevant reviews, especially in younger people with inherited severe cholesterol who need specialist continuity.

Special situations

Non-HDL survives lunch

Because it is total cholesterol minus HDL, non-HDL remains useful in a non-fasting sample and captures remnant as well as LDL atherogenic particles.

Risk calculators have boundaries

Established vascular disease and familial hypercholesterolaemia already define high risk; asking QRISK to rediscover them can falsely defer necessary treatment.

Symptoms deserve a rechallenge plan

A pause, resolution check and alternative statin can distinguish causality and retain prevention benefit more effectively than a permanent allergy label after one episode.

Fatty liver permits statins

Steatotic liver commonly coexists with vascular risk, and transaminases below three times the upper limit do not by themselves contraindicate statin treatment.

Targets follow indication

Primary prevention uses percentage non-HDL reduction, while secondary prevention now has absolute LDL or non-HDL targets; recording the indication prevents ambiguous review.

Common pitfalls

  1. 01

    Using QRISK to decide treatment after myocardial infarction.

  2. 02

    Waiting for a fasting sample before starting secondary prevention.

  3. 03

    Stopping a statin automatically for mild transaminase elevation below three times normal.

  4. 04

    Checking CK routinely in every asymptomatic person and over-interpreting exercise-related elevation.

  5. 05

    Abandoning all statins after one episode of nonspecific aching without a rechallenge strategy.

  6. 06

    Ignoring hypothyroidism, diabetes, alcohol or nephrotic syndrome as secondary causes.

  7. 07

    Treating HDL concentration as a standalone pharmacological target.

  8. 08

    Continuing ordinary statin therapy into planned pregnancy without specialist review.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Endocrinology and metabolismOriginal SBA

Secondary prevention intensity

A patient with previous myocardial infarction has no statin contraindication and is not taking lipid-lowering treatment. What is the usual NICE initial statin strategy?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Endocrinology and metabolism topics →
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG238 lipid modification recommendationsRisk assessment, statin intensity, targets, monitoring and intolerance.
  • BNF atorvastatin prescribing monographCurrent dose, interactions, hepatic, muscle and reproductive cautions.
  • NICE TA385 ezetimibe recommendationsUse as monotherapy or additional LDL-lowering treatment.
  • NICE TA733 inclisiran recommendationsEligibility for injectable LDL lowering in selected high-risk adults.
  • NICE NG49 steatotic liver recommendationsLiver assessment and statin continuation in metabolic steatotic liver disease.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
  • Use a non-fasting profile for routine assessment: total cholesterol, HDL cholesterol, non-HDL cholesterol and triglycerides, calculating LDL when analytically appropriate.
  • For primary prevention, NICE recommends offering atorvastatin 20 mg when QRISK3 is 10% or more and considering it below 10% when risk may be underestimated or the person prefers treatment.
  • For established cardiovascular disease, offer atorvastatin 80 mg unless interaction, adverse-effect risk or preference justifies a lower dose; do not recalculate QRISK.
  • NICE aims for more than 40% reduction in non-HDL cholesterol in primary prevention after treatment starts.
  • For secondary prevention, current NICE targets are LDL cholesterol 2.0 mmol/L or less, or non-HDL cholesterol 2.6 mmol/L or less.
  • Check secondary causes and baseline safety: alcohol, diabetes, hypothyroidism, liver or renal disease, nephrotic syndrome, diet and medicines.
  • Measure baseline liver transaminases, renal function and diabetes status; check creatine kinase before treatment only when persistent unexplained muscle symptoms are present.
  • Mild stable transaminase elevation below three times the upper limit does not routinely exclude statin treatment, including in steatotic liver disease.
  • 05
    Creatine kinase for muscle symptoms
    Why
    Assess possible myopathy before or during statin treatment.
    Interpretation and limitations
    Routine CK in an asymptomatic person is unnecessary. Interpret elevation with exercise, thyroid disease and renal function; marked symptoms or very high CK requires immediate cessation and acute assessment.
  • 06
    Repeat lipids and liver transaminases
    Why
    Measure response, adherence and early hepatic safety after treatment change.
    Interpretation and limitations
    At two to three months, seek over 40% non-HDL reduction for primary prevention or the secondary-prevention LDL/non-HDL target; investigate non-response before assuming biological resistance.
  • 07
    Pregnancy assessment where relevant
    Why
    Avoid routine lipid-lowering exposure during pregnancy and plan conception safely.
    Interpretation and limitations
    Stop ordinary statin therapy and seek lipid-obstetric advice for very high inherited risk; gestational lipids are physiologically altered and should not trigger casual dose escalation.
  • 2Review adherence and maximise tolerated statin, aiming for LDL at most 2.0 mmol/L or non-HDL at most 2.6 mmol/L under current NICE guidance.
  • 3Add ezetimibe and follow commissioned inclisiran, PCSK9 or other specialist pathways when the target remains unmet on maximally tolerated oral therapy.
    • 03Muscle symptomsPreserve benefit while testing causalityNew unexplained muscle pain, tenderness or weakness occurs during statin treatment.+
    1. 1Assess severity, dark urine, CK, renal function, thyroid disease, recent exercise, infection and interacting medicines; stop immediately and admit if rhabdomyolysis is possible.
    2. 2For non-severe symptoms, pause and observe resolution, then rechallenge with the same or another statin at a lower dose through shared decision-making.
    3. 3Use the maximum tolerated regimen and add non-statin therapy when indicated rather than abandoning LDL lowering after one unstructured trial.
    04Unexpected lipid resultFind inherited or secondary diseaseCholesterol or triglycerides are markedly elevated or change abruptly.+
    1. 1Repeat a credible profile and review diabetes control, alcohol, thyroid, renal, liver, pregnancy, diet and medicines before calling the pattern primary.
    2. 2Use Simon Broome or Dutch criteria and family history for severe LDL elevation, referring suspected FH for specialist and cascade assessment.
    3. 3Use the severe-hypertriglyceridaemia pathway for concentrations above 10 mmol/L and urgently assess abdominal pain rather than relying on statin monotherapy.
    Provides substantial additional LDL lowering for selected high-risk patients not at target on tolerated oral therapy.

    Inclisiran or PCSK9-targeted therapy

    Use only the product-specific subcutaneous loading and maintenance regimen through the current NICE-commissioned specialist or primary-care pathway after eligibility and baseline LDL are confirmed.

    Eligibility thresholds, commissioning and administration ownership differ by product and jurisdiction. Review pregnancy, injection reactions, adherence to background therapy and follow-up lipids; do not treat a laboratory number without the indicated risk context.

    Repeat lipids and liver tests two to three months after starting or changing treatment, then act on adherence, response and adverse effects rather than prescribing without feedback.
  • When targets are not reached on maximally tolerated statin, add or refer for ezetimibe, inclisiran, PCSK9 therapy or bempedoic-acid pathways according to indication and current commissioning.
  • Pregnancy and breastfeeding require a separate lipid-specialist plan; routine statins are stopped before conception and avoided during pregnancy under current UK product guidance.